Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease.

Ethambutol (EMB) is an important component of multidrug treatment regimens for Mycobacterium avium complex lung disease. Ocular toxicity is the most important potential EMB toxicity, especially in the elderly population with M. avium complex lung disease. Two hundred twenty-nine patients with M. avium complex lung disease, 55% women and 53% with nodular/bronchiectatic disease, received a mean of 16.1 +/- 10.8 months of multidrug therapy that included EMB. Fifty patients (22%) were known to have preexisting ocular disease. While on EMB, 97 (42%) patients consulted an opthalmologist and 24 (10%) stopped EMB at least temporarily. Eight of 139 patients (6%) on daily therapy were diagnosed with EMB ocular toxicity, whereas 0 of 90 patients on intermittent therapy had EMB ocular toxicity (p = 0.05). All patients with EMB ocular toxicity developed symptoms between outpatient clinic appointments; none were diagnosed with routine visual acuity and color vision testing. All patients with EMB ocular disease returned to baseline ocular status after discontinuation of EMB. Intermittent EBM administration was associated with less ocular toxicity than daily EMB administration in this patient population.

[1]  R. Wallace,,et al.  Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Buchanan,et al.  Ocular toxicity following ethambutol in standard dosage. , 1986, British journal of diseases of the chest.

[3]  K. Alvarez,et al.  Ethambutol-Induced Ocular Toxicity Revisited , 1993, The Annals of pharmacotherapy.

[4]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[5]  W. Addington.  The side effects and interactions of antituberculosis drugs. , 1979, Chest.

[6]  J. Singer,et al.  A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. , 1996, The New England journal of medicine.

[7]  A. Niimi,et al.  Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[8]  J. Leibold,et al.  THE OCULAR TOXICITY OF ETHAMBUTOL AND ITS RELATION TO DOSE * , 1966, Annals of the New York Academy of Sciences.

[9]  D. Menzies,et al.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[10]  Russo Pa,et al.  Toxic optic neuropathy associated with ethambutol: implications for current therapy. , 1994 .

[11]  C. Horsburgh,et al.  A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Snider,et al.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. , 1994, American journal of respiratory and critical care medicine.

[13]  R. Wallace,,et al.  Diagnosis and treatment of disease caused by nontuberculous mycobacteria. , 1990, The American review of respiratory disease.

[14]  L. Hudson,et al.  High dose ethambutol; an oral alternate for intermittent chemotherapy. , 1974, The American review of respiratory disease.

[15]  H. David Humes,et al.  Kelley's textbook of internal medicine , 2000 .

[16]  Atul Kumar,et al.  Ocular ethambutol toxicity: is it reversible? , 1993, Journal of clinical neuro-ophthalmology.

[17]  A. Denison,et al.  Treating multidrug-resistant tuberculosis: compliance and side effects. , 1994, JAMA.

[18]  R. Baughman.  Cytomegalovirus: the monster in the closet? , 1997, American journal of respiratory and critical care medicine.

[19]  R. Wallace,,et al.  Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. , 1996, American journal of respiratory and critical care medicine.

[20]  Kahana Lm.  Toxic ocular effects of ethambutol , 1987 .

[21]  Paige L. Williams,et al.  A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  G. O. Thomas,et al.  Ocular toxicity from ethambutol. , 1986, Thorax.

[23]  B. Fox,et al.  Rapid-onset reversible ocular toxicity from ethambutol therapy. , 1991, The American journal of medicine.

[24]  R. Albert,et al.  High-dose ethambutol: its role in intermittent chemotherapy. A six-year study. , 1976, The American review of respiratory disease.